← Leaderboards
Lawrence S. Zisman
University Of Colorado Denver
$5,312,556
Attributed
$6,448,808
Total exposure
6
Grants
5
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $1.6M · FY2010–17$2M$1.5M$1M$500K$0
'10
'11
'12
'13
'14
'15
'16
'17
Funding mix
By agency
NIH$6,448,808 · 6
By mechanism
R44$5,271,635 · 1
R43$999,961 · 3
R03$145,000 · 1
M01$32,212 · 1
Top collaborators
- Jeffrey Breit3 shared
Most similar at University Of Colorado Denver
Same institution · by research overlap
- Matthew R Taylor$5,502,265
- Antonio Jimeno$15,496,689
- Brian L Stauffer$5,871,842
- Michael R. Bristow$7,111,960
- Keith B Neeves$6,451,133
Others in their field
Top investigators on “Clinical Trials”
- Lawrence Corey · Fred Hutchinson Cancer Center$824,102,536
- Sonia M Thomas · Research Triangle Institute$700,865,642
- David Heimbrook · Leidos Biomedical Research, Inc.$622,583,125
- Margaret Juliana McElrath · Fred Hutchinson Cancer Center$542,008,718
- Bambra Strokes · Ppd Development Lp$526,656,217
- Judith S. Currier · University Of California Los Angeles$504,273,077
Research focus
Clinical TrialsMorbidity - Disease RateLeadPulmonary Arterial HypertensionSmall Business Innovation Research GrantBreathingRattusInhibitor/AntagonistDrug KineticsDosePharmaceutical PreparationsSocietiesMortality Vital StatisticsProtocols DocumentationPublic Health Medicine (Field)LungPhosphotransferasesPublic Health RelevanceKinase InhibitorPowder Dose FormPlatelet-Derived Growth Factor ReceptorInnovationRare DiseasesTyrosine Kinase Inhibitor
Grant awards (13)
An inhaled PDGF receptor inhibitor for the treatment of pulmonary arterial hypertension$999,751
R44 · FY2017 · HL · contact PI
An inhaled PDGF receptor inhibitor for the treatment of pulmonary arterial hypertension$999,482
R44 · FY2016 · HL · contact PI
A novel inhaled c-kit/PDGFR inhibitor for the treatment of asthma$337,324
R43 · FY2016 · HL · contact PI
An inhaled PDGF receptor inhibitor for the treatment of pulmonary arterial hypertension$999,898
R44 · FY2015 · HL · contact PI
An inhaled PDGF receptor inhibitor for the treatment of pulmonary arterial hypertension$5,000
R44 · FY2015 · HL · contact PI
An inhaled PDGF receptor inhibitor for the treatment of pulmonary arterial hyper$701,052
R44 · FY2013 · HL · contact PI
An inhaled PDGF receptor inhibitor for the treatment of pulmonary arterial hyper$1,566,452
R44 · FY2012 · HL · contact PI
Phosphopeptide mapping of plexiform lesions in pulmonary arterial hypertension$72,500
R03 · FY2012 · HL · contact PI
Phosphopeptide mapping of plexiform lesions in pulmonary arterial hypertension$72,500
R03 · FY2011 · HL · contact PI
A PDGFR inhibitor for the treatment of pulmonary arterial hypertension$351,008
R43 · FY2010 · HL · contact PI
A novel JAK inhibitor for the treatment of pulmonary arterial hypertension$311,629
R43 · FY2010 · HL · contact PI
EFFECT OF CARDIAC TISSUE SPECIFIC ANGIOTENSIN CONVERTING ENZYME INHIBITION$32,212
M01 · FY2000 · RR
EFFECT OF CARDIAC TISSUE SPECIFIC ANGIOTENSIN CONVERTING ENZYME INHIBITION$0
M01 · FY2000 · RR